Targeting Myc-driven stress addiction in colorectal cancer
MYC is a proto-oncogene that encodes a powerful regulator of transcription and cellular
programs essential for normal development, as well as the growth and survival of various …
programs essential for normal development, as well as the growth and survival of various …
Beyond cisplatin: New frontiers in metallodrugs for hard-to-treat triple negative breast cancer
N Muhammad, M Hanif, P Yang - Coordination Chemistry Reviews, 2024 - Elsevier
Triple-negative breast cancer (TNBC) is the most aggressive and hard-to-treat form of breast
cancer. TNBC has a higher propensity for earlier relapse and an increased risk of metastasis …
cancer. TNBC has a higher propensity for earlier relapse and an increased risk of metastasis …
Histone‐lysine N‐methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc‐driven liver cancer
Hepatocellular carcinoma (HCC) is the third deadliest and sixth most common cancer in the
world. Histone‐lysine N‐methyltransferase EHMT2 (also known as G9a) is a histone …
world. Histone‐lysine N‐methyltransferase EHMT2 (also known as G9a) is a histone …
Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation
Y Zhong, J Xu, R Zhou, L Tang, S Ding… - Journal of Medicinal …, 2024 - ACS Publications
Cyclin-dependent kinase 9 (CDK9) is a member of the transcription CDK subfamily. In this
work, we preliminarily demonstrated the feasibility of CDK9 as a potent target of treatment for …
work, we preliminarily demonstrated the feasibility of CDK9 as a potent target of treatment for …
Addressing transcriptional dysregulation in cancer through CDK9 inhibition
MA Toure, AN Koehler - Biochemistry, 2023 - ACS Publications
Undermining transcriptional addiction, the dependence of cancers on selected
transcriptional programs, is critically important for addressing cancers with high unmet …
transcriptional programs, is critically important for addressing cancers with high unmet …
CDK9 inhibitor induces apoptosis, autophagy, and suppression of tumor growth in adult T-cell leukemia/lymphoma
N Kato, T Kozako, T Ohsugi, Y Uchida… - Biological and …, 2023 - jstage.jst.go.jp
Adult T-cell leukemia/lymphoma (ATL) is a hematopoietic malignancy with a poor prognosis
that develops in approximately 5% of human T-cell leukemia virus type 1 (HTLV-1) carriers …
that develops in approximately 5% of human T-cell leukemia virus type 1 (HTLV-1) carriers …
[HTML][HTML] Bone marrow microenvironment-induced regulation of Bcl-2 family members in multiple myeloma (MM): therapeutic implications
O Aksoy, J Lind, V Sunder-Plaßmann, S Vallet, K Podar - Cytokine, 2023 - Elsevier
Abstract In Multiple Myeloma (MM) the finely tuned homeostasis of the bone marrow (BM)
microenvironment is disrupted. Evasion of programmed cell death (apoptosis) represents a …
microenvironment is disrupted. Evasion of programmed cell death (apoptosis) represents a …
Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients
M Beltrán‐Visiedo, N Jiménez‐Alduán… - Molecular …, 2023 - Wiley Online Library
A better understanding of multiple myeloma (MM) biology has led to the development of
novel therapies. However, MM is still an incurable disease and new pharmacological …
novel therapies. However, MM is still an incurable disease and new pharmacological …
De novo transcriptome analysis of Dysoxylum binectariferum to unravel the biosynthesis of pharmaceutically relevant specialized metabolites
PM Kumara, E Varun, JR Sanjay… - Frontiers in Plant …, 2023 - frontiersin.org
The tropical tree, D. binectariferum, is a prominent source of chromone alkaloid rohitukine,
which is used in the semi-syntheses of anticancer molecules such as flavopiridol and P-276 …
which is used in the semi-syntheses of anticancer molecules such as flavopiridol and P-276 …
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
A Soosainathan, M Iravani, R El-Botty, J Alexander… - Cancer Research, 2024 - AACR
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an
effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet …
effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet …